thiamine
Approved
Jul 28, 1947
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency. — NCATS
Clinical trial activity
129 trials · 195 clinical orgs · 28 marketing orgs
Earliest trial started Aug 1, 2001 (NCT00143702)
Timeline
1940s
1970s
- Jun 20, 1972
Fresenius — Marketing Organization
- Dec 6, 1972
Parke-Davis — Marketing Organization
- Dec 6, 1972
Warner Lambert — Marketing Organization
- Feb 4, 1974
Belmar Pharmacy — Marketing Organization
- Feb 26, 1974
Watson Pharmaceuticals — Marketing Organization
- Feb 26, 1974
Dr. Reddy's Laboratories — Marketing Organization
- Mar 27, 1974
American Home Products — Marketing Organization
- Aug 6, 1974
Del Laboratories — Marketing Organization
- Jun 24, 1975
West-Ward Pharmaceutical — Marketing Organization
1980s
- Nov 6, 1981
Abraxis — Marketing Organization
- Nov 6, 1981
Abraxis — NDA Secondary Org
- Jul 13, 1982
Watson Pharmaceuticals — NDA Secondary Org
2000s
2010s
- Jun 25, 2012
Mylan — Marketing Organization
- Dec 1, 2017
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Dec 1, 2017
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
2020s
- Apr 20, 2022
Eugia Pharma — Marketing Organization
- Mar 6, 2023
Caplin Point Laboratories — Marketing Organization
- Oct 29, 2024
STERISCIENCE — Marketing Organization
- Oct 29, 2024
ONESOURCE SPECIALTY — Marketing Organization
- Nov 6, 2024
Aspiro — Marketing Organization
- Feb 24, 2025
Gland Pharma Ltd — Marketing Organization
- Apr 9, 2026
Apotex — Marketing Organization
Indications
Approved for
Studied for
- Acidosis, Lactic · Phase 4
- Acquired Immunodeficiency Syndrome · Phase 4
- Acute Lung Injury · Phase 2/Phase 3
- Aging · Phase 1/Phase 2
- Alcoholism · Phase 4
- Alcohol Withdrawal Delirium · Phase 2/Phase 3
- Alzheimer Disease · Phase 2
- Amyotrophic Lateral Sclerosis · Phase 1
- Anemia · Phase 4
- Anemia, Pernicious · Phase 4
- Beriberi · Phase 1
- Blood · Phase 4
- Body Fluids · Phase 4
- Brain Injuries · Phase 2
- Cardiac Surgical Procedures · Phase 2
- Cardiopulmonary Bypass · Phase 4
- Cardiovascular Diseases · Early Phase 1
- Child · Phase 4
- Cognitive Dysfunction · Early Phase 1
- Coronary Artery Bypass · Phase 2
- Coronary Disease · Early Phase 1
- COVID-19 · Phase 4
- Critical Care · Phase 4
- Critical Illness · Phase 4
- Deficiency Diseases · Phase 4
- Delirium · Phase 2
- Depression · Early Phase 1
- Diabetes Mellitus · Phase 2
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Ketoacidosis · Phase 2
- Diabetic Nephropathies · Phase 4
- Diabetic Neuropathies · Phase 3
- Disability Evaluation · Early Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Ductus Arteriosus, Patent · Early Phase 1
- Endothelial Cells · Phase 4
- Essential Hypertension · Phase 4
- Fatigue · Phase 4
- Hair · Phase 4
- Healthy Volunteers · Phase 3
- Heart Arrest · Phase 2
- Heart Defects, Congenital · Phase 4
- Heart Diseases · Phase 3
- Heart Failure · Phase 4
- Heart Failure, Systolic · Phase 1
- Heart Septal Defects, Atrial · Early Phase 1
- Heart Septal Defects, Ventricular · Early Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hepatitis B, Chronic · Phase 4
- HIV · Phase 2
- HIV Infections · Phase 4
- Hormones · Early Phase 1
- Huntington Disease · Phase 2
- Hyperemesis Gravidarum · Phase 3
- Hyperlipidemias · Early Phase 1
- Hyperphagia · Early Phase 1
- Hypertension · Phase 4
- Hyperthermia · Phase 1
- Inflammation · Early Phase 1
- Insulin Resistance · Early Phase 1
- Kidney Diseases · Phase 2
- Korsakoff Syndrome · Phase 4
- Lipodystrophy · Phase 4
- Liver Cirrhosis, Biliary · Phase 4
- Magnesium Deficiency · Phase 2/Phase 3
- Metabolic Diseases · Phase 2/Phase 3
- Metabolism · Phase 1
- Migraine Disorders · Phase 1/Phase 2
- Migraine with Aura · Phase 1/Phase 2
- Neoplasms · Phase 3
- Neoplastic Stem Cells · Phase 2
- Obesity · Phase 4
- Out-of-Hospital Cardiac Arrest · Phase 2
- Post-Acute COVID-19 Syndrome · Phase 4
- Post-Cardiac Arrest Syndrome · Phase 2
- Pregnancy Complications · Phase 4
- Quality of Life · Phase 2
- Respiratory Distress Syndrome · Phase 2/Phase 3
- Respiratory Insufficiency · Phase 2
- Sedentary Behavior · Early Phase 1
- Sepsis · Phase 4
- Shock · Phase 2
- Shock, Septic · Phase 4
- Sports Medicine · Phase 1
- Steatitis · Phase 4
- Stroke · Phase 1
- Subarachnoid Hemorrhage · Phase 3
- Thiamine · Phase 2
- Thiamine Deficiency · Phase 4
- Thoracic Surgery · Phase 4
- Tryptophan · Phase 2
- Ureteral Diseases · Early Phase 1
- Vasoplegia · Phase 2
- Vertigo · Phase 4
- Wernicke Encephalopathy · Phase 2/Phase 3
- Wounds and Injuries · Phase 3
Mechanism of action
- Thiamine transporter 1INHIBITOR
SLC19A2 inhibitor
- Unspecified targetOTHER
Supplement
Combination products
berocca pn
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, biotin, panthenol, pyridoxine, riboflavin, vitamin a, ergocalciferol
Also known as m.v.c, mvc plus
infuvite
with vitamin d3, vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, vitamin k, biotin, panthenol, pyridoxine, riboflavin, vitamin a
Also known as infuvite pediatric, infuvite pediatric (pharmacy bulk package)
m.v.i. adult (pharmacy bulk package)
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, vitamin k, biotin, panthenol, pyridoxine, riboflavin, vitamin a, ergocalciferol
m.v.i. pediatric
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, biotin, panthenol, pyridoxine, riboflavin, vitamin a, phytonadione, ergocalciferol
vitape
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, pantothenic acid, biotin, pyridoxine, riboflavin, vitamin a, phytonadione, ergocalciferol
Approval history
- approvedJul 28, 1947
Chemistry & pharmacology
SMILES
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-]- Mol. weight
- 300.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaThiamine ↗
- ChEMBLCHEMBL1588 ↗
- NCATS4ABT0J945J ↗
- ChEMBLCHEMBL2104496 ↗
- ChEMBLCHEMBL1200941 ↗
- WikipediaFursultiamine ↗
- ChEMBLCHEMBL1491875 ↗
- ChEMBLCHEMBL1740659 ↗
- ChEMBLCHEMBL1547 ↗
Also known as
- 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
- 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
- 8088 c.b
- 8088 c.b
- aneurin
- aneurin
- aneurine hcl
- aneurine hcl
- antiberiberi factor
- antiberiberi factor
- benerva
- benerva
- benfothiamine
- benfothiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benfotiamine
- benphothiamine
- benzoylthiamine monophosphate
- benzoylthiaminmonophosphat
- benzoylthiaminmonophosphat
- betalin s
- betalin s
- betaxin
- betaxin
- betivina
- bevitine
- bevitine
- bevitol
- bietamine
- btmp-benfo
- diteftin
- fursultiamin
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine
- fursultiamine hcl
- fursultiamine hcl
- fursultiamine hcl
- fursultiamine hydrochloride
- judolor
- judolor
- milgamma
- neurostop
- n,n'-(dithiobis(2-(2-hydroxyethyl)-1-methylvinylene))bis(n-((4-amino-2-methyl-5-pyrimidinyl)-methyl)formamide)
- s-benzoylthiamine monophosphate
- s-benzoylthiamine o-monophosphate
- tetrahydrofurfuryl thiamine disulfide
- thiamin
- thiamin
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine
- thiamine(1+)
- thiamine(1+)
- thiamine(1+) ion
- thiamine(1+) ion
- thiamine disulfide
- thiamine disulfide
- thiamine disulfide
- thiamine disulphide
- thiamine hcl
- thiamine hcl
- thiamine hcl
- thiamine hydrochloride
- thiamine hydrochloride
- thiamine hydrochloride
- thiamine hydrochloride
- thiamine hydrochloride
- thiamine mononitrate
- thiamine tetrahydrofurfuryl disulfide
- thiamine (vit b1)
- thiamine (vit b1)
- thiamine (vit b1)
- thiaminium
- thiaminium
- thiamin tetrahydrofurfuryl disulfide
- ttfd
- ttfd
- tyvera
- vitamin b1
- vitamin b1
- vitamin b1
- vitamin b1
- vitamin b1
- vitamin b1
- vitamin b 1
- vitamin b 1
- vitamins b1
- vit b1
- vit b1 thiamin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06959251 | N/A | Oct 2, 2025 | Instituto Nacional de Enfermedades Respiratorias |
| NCT07046429 | N/A | Aug 5, 2025 | American Association for the Study of Liver Diseases, Cornell University |
| NCT06326996 | Early Phase 1 (Phase 1) | Oct 10, 2024 | University of California, Los Angeles |
| NCT06322212 | N/A | Aug 1, 2024 | National Institute on Aging (NIA), University of California, Los Angeles |
| NCT06298344 | Early Phase 1 (Phase 1) | May 1, 2024 | Universitas Sumatera Utara |
| NCT06649825 | N/A | Jan 8, 2024 | Fudan University |
| NCT07304453 | Phase 2 | Jan 7, 2024 | Karbala University, Kufa University |
| NCT05817851 | Phase 2 | Jan 1, 2024 | Centre Hospitalier de Béthune, Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, University of Lille |
| NCT05873881 | Phase 3 | Nov 30, 2023 | Canadian Institutes of Health Research (CIHR), Hamilton Health Sciences Corporation, McMaster University |
| NCT06122701 | N/A | Nov 20, 2023 | University of Greifswald |
| NCT05971680 | Phase 3 | Jul 30, 2023 | Beni Suef University |
| NCT06242535 | Early Phase 1 (Phase 1) | Jul 27, 2023 | Buck Institute for Research on Aging, Hoskinson Health and Wellness Clinic, University of Wyoming |
| NCT05642923 | Phase 4 | Dec 8, 2022 | Cairo University, ClinAmygate |
| NCT05385042 | Phase 4 | Jun 18, 2022 | University of Oxford |
| NCT05083546 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2022 | University of California, San Francisco |
| NCT04478734 | Phase 2 | Jan 1, 2022 | Centro de Investigación Biomédica en Red (CIBER), Fundación Pública Andaluza, University of Seville, Virgen del Rocío University Hospital, Seville |
| NCT05221892 | Phase 4 | Nov 22, 2021 | Fundação Educacional Serra dos Órgãos |
| NCT04651205 | N/A | Oct 31, 2021 | University of Glasgow |
| NCT04999137 | Phase 2 | Sep 1, 2021 | Infectious Disease Institute, Kampala, Uganda, LSTM/IDI/Walimu, University of Copenhagen, University of Liverpool, Walimu |
| NCT04880889 | Phase 3 | Sep 1, 2021 | Biolab Sanus Farmaceutica, Medcin Instituto da Pele |
Organizations
Research & Development (195)
Marketing (36)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | MKTG | Nov 6, 1981 |
| Abraxis | For profit | NDA2 | Nov 6, 1981 |
| Akorn, Inc. | For profit | MKTG | — |
| American Home Products | For profit | MKTG | Mar 27, 1974 |
| Apotex | For profit | MKTG | Apr 9, 2026 |
| Aspiro | For profit | MKTG | Nov 6, 2024 |
| Belmar Pharmacy | For profit | MKTG | Feb 4, 1974 |
| Caplin Point Laboratories | For profit | MKTG | Mar 6, 2023 |
| Del Laboratories | For profit | MKTG | Aug 6, 1974 |
| Dr. Reddy's Laboratories | For profit | MKTG | Feb 26, 1974 |
| Eli Lilly | For profit | MKTG | — |
| Eugia Pharma | For profit | MKTG | Apr 20, 2022 |
| Fresenius | For profit | MKTG | Jun 20, 1972 |
| Gland Pharma Ltd | For profit | MKTG | Feb 24, 2025 |
| Hospira | For profit | MKTG | Feb 20, 1953 |
| Hospira | For profit | NDA2 | Feb 20, 1953 |
| Lutipold | For profit | MKTG | — |
| Mylan | For profit | MKTG | Jun 25, 2012 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Dec 1, 2017 |
| Novartis | For profit | NDA2 | May 18, 2000 |
| ONESOURCE SPECIALTY | For profit | MKTG | Oct 29, 2024 |
| Parke-Davis | For profit | MKTG | Dec 6, 1972 |
| Roche | For profit | MKTG | Jul 28, 1947 |
| Roche | For profit | NDA2 | Jul 28, 1947 |
| Roche | For profit | NDA | Jul 28, 1947 |
| STERISCIENCE | For profit | MKTG | Oct 29, 2024 |
| STERISCIENCE | For profit | SYN | Oct 29, 2024 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Dec 1, 2017 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Dec 1, 2017 |
| Sandoz | For profit | MKTG | May 18, 2000 |
| Sandoz | For profit | NDA2 | May 18, 2000 |
| Teligent Pharmaceuticals | For profit | NDA2 | — |
| Warner Lambert | For profit | MKTG | Dec 6, 1972 |
| Watson Pharmaceuticals | For profit | MKTG | Feb 26, 1974 |
| Watson Pharmaceuticals | For profit | NDA2 | Jul 13, 1982 |
| West-Ward Pharmaceutical | For profit | MKTG | Jun 24, 1975 |